MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Sanofi SA Company Profile (NYSE:SNY)

Consensus Ratings for Sanofi SA (NYSE:SNY) (?)
Ratings Breakdown: 3 Sell Rating(s), 5 Hold Rating(s), 5 Buy Rating(s)
Consensus Rating:Hold (Score: 2.15)
Consensus Price Target: $51.50 (23.06% upside)

Analysts' Ratings History for Sanofi SA (NYSE:SNY)
Show:
DateFirmActionRatingPrice TargetActions
6/28/2016Citigroup Inc.Reiterated RatingNeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/12/2016BarclaysUpgradeEqual Weight -> OverweightView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/3/2016HSBCDowngradeBuy -> HoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/3/2016Bank of AmericaReiterated RatingBuy$58.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/25/2016JPMorgan Chase & Co.Reiterated RatingSellView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/12/2016Chardan CapitalReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/18/2016Goldman SachsReiterated RatingNeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/10/2016Sanford C. BernsteinLower Price TargetMarket-Perform$52.00 -> $45.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/16/2015Oddo SecuritiesDowngradeReduceView Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/10/2015BNP ParibasDowngradeNeutral -> UnderperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/1/2015Morgan StanleyDowngradeOverweight -> Equal WeightView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/9/2015Bryan, Garnier & CoReiterated RatingBuy -> NeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/16/2015Sarasin & PartnersUpgradeBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/13/2015Deutsche BankUpgradeBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/15/2015Societe GeneraleInitiated CoverageBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/17/2015Leerink SwannUpgradeMarket Perform -> OutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/23/2015Kepler Capital MarketsDowngradeHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/29/2014Jefferies GroupDowngradeBuy -> HoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/15/2014Credit SuisseUpgradeNeutral -> OutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/11/2014Berenberg BankDowngradeBuy -> HoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/28/2014Main First Bank AGUpgradeOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/1/2014 forward)
Earnings History for Sanofi SA (NYSE:SNY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
10/29/2015Q315$0.88$0.89ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/30/2015Q115$0.61$0.73ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/5/2015Q4$0.89$0.79ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/31/2014Q2$0.79$0.72ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/29/2014Q114$0.84$0.81ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/6/2014Q4$0.88$0.93ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/30/2013$1.01$0.93ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Sanofi SA (NYSE:SNY)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162$0.65$0.72$0.69
Q2 20161$0.75$0.75$0.75
Q3 20161$0.84$0.84$0.84
Q4 20161$0.78$0.78$0.78
(Data provided by Zacks Investment Research)
Current Dividend Information for Sanofi SA (NYSE:SNY)
Annual Dividend:$1.63
Dividend Yield:3.89%
Payout Ratio:50.78%
Dividend Growth:-1.60% (3 Year Average)

Dividend History for Sanofi SA (NYSE:SNY)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable DateShare
2/22/2016Annual$1.105/5/20165/9/20166/1/2016Tweet This Announcement  Share This Announcement on StockTwits
2/26/2015special$1.623.91%5/6/20155/8/20156/2/2015Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2013 forward)
Insider Trading History for Sanofi SA (NYSE:SNY)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
7/9/2014SanofiMajor ShareholderBuy195,000$308.27$60,112,650.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/8/2014SanofiMajor ShareholderBuy153,000$311.67$47,685,510.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Sanofi SA (NYSE:SNY)
DateHeadline
07/01/16 09:02 AMHere's Why Regeneron Pharmaceuticals Inc Is Down 35% This Year -
06/28/16 01:30 PMSanofi Agrees to $25.1B Asset Swap (SNY) -
06/27/16 10:38 AMSanofi (NYSE:SNY) Sellers Increased By 4.03% Their Shorts - Engelwood Daily
06/25/16 11:05 AMHow Was Roche’s Operational Performance in 2Q16? -
06/24/16 06:35 PMAllergan plc Ordinary Shares (NYSE:AGN) & Sanofi SA (NYSE:SNY) Healthcare Stocks in Focus - Wall Street 24
06/24/16 06:35 PMSanofi SA (NYSE:SNY) Adds Costa Rica To Dengvaxia Approval List - Market Exclusive
06/24/16 09:04 AMSanofi SA (NYSE:SNY) Adds Costa Rica To Dengvaxia Approval List
06/22/16 06:26 PMInovio Pharmaceuticals Inc (NASDAQ:INO) Jumps Ahead Of Sanofi (SNY) In Zika Vaccine Program - Market Exclusive
06/20/16 07:57 AMBiotech stocks are in for more election trouble on drug pricing -
06/20/16 04:25 AMBioMed Realty exec on why Kendall Square lab space is still in such demand -
06/14/16 09:00 PMADVA launches Dengue Mission Buzz Barometer tool to boost critical dengue prevention awareness and preparedness amongst ASEAN Community - [PR Newswire] - SINGAPORE, June 15, 2016 /PRNewswire/ -- In support of the 6 th Association of Southeast Asian Nations (ASEAN) Dengue Day, the Asian Dengue Vaccination Advocacy (ADVA) is launching the Dengue Mission Buzz ...
06/14/16 10:01 AMRegeneron: Nine Reasons Praluent Could Be Forced From the US Market -
06/13/16 11:50 AMUPDATE 1-Sanofi, Medivation advance to next phase of takeover fight - [Reuters] - French drugmaker Sanofi and its takeover target Medivation Inc on Monday said they had filed official materials with the U.S. Securities and Exchange Commission, as their $9.3 billion battle advances to the next phase. The announcements, which for Sanofi was the filing of definitive proxy materials and for Medivation the filing of a definitive consent revocation statement, signify that the documents have received the agency's blessing. Sanofi wants to oust the board of Medivation, in order to put in place directors in support of its $52.50 offer to buy the U.S. cancer drug company.
06/13/16 11:07 AMETF’s with exposure to Sanofi : June 13, 2016 -
06/07/16 06:35 AMBoston area tops new report on early stage biotech research, employment -
06/03/16 07:09 PMSanofi SA May Raise its Medivation Inc Bid “Considerably”: Credit Suisse
05/26/16 01:33 AMSanofi Seeks to Oust Medivation Board in Formidable Takeover Attempt - Sanofi SA (ADR) (NYSE:SNY) is once again proving to be a formidable acquirer. The French drugmaker, which threatened to go hostile in its takeover pursuit of biotech company Medivation Inc. earlier this month, is now seeking to remove the latter’s entire ...
05/25/16 03:15 PMWhy Sanofi SA (ADR) (SNY) Is Trending on Wednesday - Insider Monkey (blog) - Insider Monkey (blog)Why Sanofi SA (ADR) (SNY) Is Trending on WednesdayInsider Monkey (blog)Sanofi SA (ADR) (NYSE:SNY) is preparing to oust all the board members of Medivation, Reuters reported on Wednesday, citing people familiar with the matter. The decision comes after Medivation rejected Sanofi's $9.3 billion acquisition offer last month.Is Sanofi SA (ADR) (SNY) Overvalued at Current Levels?InvestCorrectlySanofi Seeks Remove, Replace Medivation Board With Candidates Willing to Review Takeover Offer (NYSE:SNY)Sonoran Weekly ReviewSanofi Moves to Replace Medivation BoardWall Street JournalBidness ETC -Benzingaall 42 news articles »
05/25/16 02:29 PMAlnylam Soars as Drugmakers Circle Rival Biotechnology Company -
05/25/16 01:25 PMWhy Sanofi SA (ADR) (SNY) Is Trending on Wednesday -
05/24/16 10:07 AMHow Does Merial Contribute to Sanofi’s Growth? -
05/24/16 10:02 AMNew Cholesterol Treatment Now Available for Canadians - [PR Newswire] - As 8 in 10 Canadian GPs identify the need for new cholesterol treatment options, Canadian Patients now have access to PRALUENT ™ MONTREAL, May 24, 2016 /CNW Telbec/ - Sanofi Canada is pleased to announce ...
05/19/16 02:46 PMSanofi’s Growth Drivers for 1Q16 -
05/19/16 02:45 PMA Peek at Sanofi’s Valuation Cheat Sheet -
05/19/16 02:36 PMBiotech Stock Roundup: Pfizer to Buy Anacor for $5.2B, Pipeline Setbacks for Aduro, Trevena -
05/17/16 11:52 AMALK appoints Carsten Hellmann as new President and CEO - [at noodls] - May 17, 2016 Copenhagen, 2016-05-17 18:32 CEST (GLOBE NEWSWIRE) -- ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today announced that the Board of Directors has appointed Carsten Hellmann as the new President ...
05/16/16 08:00 AMSanofi Genzyme Announces Multiple Sclerosis Research Collaboration with the Johns Hopkins School of Medicine - [Business Wire] - Sanofi Genzyme, the specialty care global business unit of Sanofi, announced today a research collaboration with the Johns Hopkins School of Medicine that will focus on novel strategies aimed at advancing the understanding of underlying causes of disease progression in multiple sclerosis .
05/13/16 11:01 PM[$$] Regeneron: The Best Bet in Biotech Stocks -
05/13/16 08:40 PMSanofi to Nominate 8 Directors for Medivation Board -CNBC's Faber - Sanofi SA ( SNY) will nominate eight directors to replace Medivation Inc.'s ( MDVN) current board as soon as late next week, CNBC's David Faber reported Friday, citing people familiar with the matter. Goldman Sachs Group Inc. ( GS) and Morgan Stanley ( MS ...
05/12/16 02:27 PMSanofi Files for Hart-Scott-Rodino Notification Regarding Proposed Acquisition of Medivation - [at noodls] - Sanofi Files for Hart-Scott-Rodino Notification Regarding Proposed Acquisition of Medivation - Reiterates Commitment to Consummating Transaction - Paris, France - May 12, 2016 - Sanofi today announced ...
05/10/16 03:13 PMWhy Did Medivation’s Share Price Increase so Much after Earnings? -
05/08/16 08:40 PMMedivation Inc Takeover Talk: Sanofi May Lose Out Despite Offer To Raise Bid - Novartis AG (ADR) has also been cited as a possible seeker for Medivation. Last week, the French drug giant Sanofi SA (ADR) (NYSE:SNY) publicly offered to buy Medivation for $52.50 per share, almost a 50% premium over the company’s average share price in ...
05/08/16 01:35 AMMedivation Inc Acquisition: Sanofi SA (ADR) Won’t Take No for an Answer - Sanofi SA (ADR) (NYSE:SNY) has its eyes set on Medivation and won’t take no for an answer. The French pharmaceutical giant has said that it can raise its acquisition bid for Medivation to up to $9.3 billion — only if Medivation agrees to engage in talks.
05/06/16 08:58 AMWhat's M&A Like In The Biotech Sector Right Now? - Michael King, of JMP Securities, and Les Funtleyder, of E Squared Capital, were on CNBC Thursday discussing M&A activity in the biotech sector. The Sanofi-Medivation Deal Talking about Sanofi SA (ADR) (NYSE: SNY)’s offer for Medivation Inc (NASDAQ: MDVN), King said he believes the latter will be acquired. It’s only “a matter of time and price,” he stated. “If Sanofi is serious, I think they should raise their bid,” he added. According to JMP’s research, Medivation could justify a valuation of more than $70 per share – well above the current $59.80, just based on its lead, prostate cancer drug, Xtandi. In addition, the company counts on a “wonderful pipeline,” he assured. So, a higher bid should come, the expert concluded. Related Link: BTIG Comments On Bluebird ...Full story available on Benzinga.com
05/05/16 03:00 PMAs Sanofi hints at higher takeover price, Medivation holds its ground -
05/05/16 09:42 AMRegeneron (REGN) Tops Q1 Earnings, Ups 2016 Eylea View -
05/05/16 09:20 AMIonis Incurs Wider-than-Expected Loss in Q1, Stock Down -
05/05/16 09:09 AMRegeneron Pharmaceuticals: The Eyleas Have It -
05/04/16 03:38 PMETF’s with exposure to Sanofi : May 4, 2016 -
05/04/16 01:24 PMMizuho Downgrades Relypsa, Says Near-Term Takeout 'Unlikely' - Relypsa Inc (NASDAQ: RLYP) shares plunged more than 18 percent after Mizuho Securities downgraded the stock to Underperform from Neutral, saying the near-term buyout of the company is "unlikely" following its recent $150 million debt offering. "We view this event (offering) as a sign that near-term take-out is unlikely, which led RLYP to take on non-dilutive, but expensive financing," analyst Irina Koffler began. As a result, Koffler lowered her takeout probability to 10 percent from 50 percent, as commercial partner Sanofi SA (ADR) (NYSE: SNY) is currently bidding on Medivation Inc (NASDAQ: MDVN). It remains unclear whether other companies are interested in Relypsa. The analyst also cut the takeout value from $34/share to $31 (stripping out ...Full story available on Benzinga.com
05/04/16 11:20 AMSanofi: Annual General Shareholder Meeting of May 4, 2016 - [at noodls] - Annual General Shareholder Meeting of May 4, 2016 Shareholder approval of the financial statements for 2015 Dividend of €2.93 per share payable as of May 12, 2016 Board Composition: appointments and reappointments ...
05/03/16 09:34 AMSanofi :SNY-US: Earnings Analysis: Q1, 2016 By the Numbers -
05/03/16 06:05 AMSanofi downgraded by HSBC Securities -
04/29/16 08:20 PMDODFX: Dodge & Cox International Stock Fund Performance Case Study -
04/29/16 04:42 PM$45 Billion Thursday For M&A Shows There Are Still Plenty Of Buyers Out There - After Q1 was the weakest quarter for global M&A activity in more than two years, the M&A market showed some major signs of life this week when three major pharmaceutical deals were announced on Thursday. Abbott Laboratories (NYSE: ABT) announced a $30 billion buyout of St Jude Medical, Inc. (NYSE: STJ), AbbVie Inc (NYSE: ABBV) announced a $5.8 billion bid for Stemcentrx and Sanofi SA (ADR) (NYSE: SNY) announced a $9.3 billion offer for ...Full story available on Benzinga.com
04/29/16 01:55 AMSanofi Wants To Acquire Medivation For $52.50 Per Share - Sanofi SA (ADR) (NYSE: SNY) announced on Thursday that it has sent a letter to Medivation Inc (NASDAQ: MDVN) in which it confirmed an offer to acquire the company for $52.50 per share was proposed on April 15 and initial discussions regarding a merger were ...
04/29/16 01:55 AMSanofi Leans on Medivation to Enter Talks After $9.3B Offer - France's Sanofi (SNY - Get Report) on Thursday went public with a campaign ... based biotech and struck a research collaboration and licensing agreement with Marseilles-based Innate Pharma SA, which is working to develop treatments using antibody cells ...
04/29/16 01:55 AMDrugmakers Place Big Bets on Cancer Medicines - France’s Sanofi SA SNY-1.77 % said Thursday it made an unsolicited, $9.3 billion offer to purchase San Francisco-based Medivation Inc., MDVN 7.92 % which sells a prostate-cancer drug that recently drew criticism from members of Congress over its price tag.
04/29/16 01:55 AMSanofi Turns Hostile, Makes $9.3 Billion Bid for Medivation: A Smart Move? - Sanofi SA (ADR) (NYSE:SNY) continues to pursue Medivation Inc. (NASDAQ:MDVN), even after getting rejected by the US drug-maker two weeks ago. The French pharmaceutical giant has now publicly extended a non-binding formal proposal to acquire Medivation for ...
04/29/16 01:13 AMSanofi profits stable, strong sales in emerging markets -
About Sanofi SA

Sanofi SA logoSanofi SA is a healthcare company focused on patient needs and engaged in the research, development, manufacture and marketing of healthcare products. The Company is organized around three principal activities: Pharmaceuticals, Human Vaccines via Sanofi Pasteur, and Animal Health via Merial. The Company invests in emerging markets, diabetes solutions, vaccines, consumer health care, animal health, genzyme and other products. The emerging markets platform includes products from all three of the Company's principal activities. Under the Company's Pharmaceuticals business, products are grouped into the key fields of diabetes solutions, rare diseases, multiple sclerosis, oncology, thrombosis and cardiovascular disease prevention, nephrology and bio-surgery. The Human Vaccines activity is operated through Sanofi Pasteur. The Animal Health activity is carried out through Merial.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Drug Manufacturers - Major
  • Sub-Industry: N/A
  • Exchange: NYSE
  • Symbol: SNY
  • CUSIP:
Key Metrics:
  • Previous Close: $41.85
  • 50 Day Moving Average: $40.04
  • 200 Day Moving Average: $40.82
  • P/E Ratio: 22.19
  • P/E Growth: 1.84
  • Market Cap: $107.20B
  • Current Quarter EPS Consensus Estimate: $3.16 EPS
Additional Links:
Sanofi SA (NYSE:SNY) Chart for Friday, July, 1, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha